Shanghai Henlius Biotech
Shanghai Henlius Biotech, also known as Henlius, is a prominent biopharmaceutical company headquartered in Shanghai, China. Founded in 2010, the company has rapidly established itself in the biotechnology industry, focusing on the research, development, and manufacturing of innovative monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. With a strong operational presence in both domestic and international markets, Henlius has achieved significant milestones, including the successful launch of its flagship products, which are distinguished by their high quality and affordability. The company is recognised for its commitment to advancing biopharmaceutical solutions, positioning itself as a key player in the global market. Henlius continues to expand its portfolio, aiming to enhance patient outcomes through cutting-edge therapies.
DitchCarbon Score
How does Shanghai Henlius Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai Henlius Biotech's score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shanghai Henlius Biotech's reported carbon emissions
In 2023, Shanghai Henlius Biotech reported total carbon emissions of approximately 21,973,000 kg CO2e. This figure includes about 6,908,630 kg CO2e from Scope 1 emissions and approximately 15,064,370 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Comparatively, in 2021, the total emissions were about 23,543,440 kg CO2e, with Scope 1 contributing approximately 6,249,150 kg CO2e and Scope 2 accounting for about 17,294,290 kg CO2e. This indicates a reduction in total emissions from 2021 to 2023. Despite these figures, Shanghai Henlius Biotech has not set specific reduction targets or initiatives, nor have they committed to any climate pledges or SBTi targets. The absence of documented reduction initiatives suggests that the company may be in the early stages of developing a comprehensive climate strategy. Overall, while the company has made strides in reducing its emissions over the past two years, further commitments and structured reduction targets will be essential for aligning with industry standards and addressing climate change effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2023 | |
|---|---|---|---|
| Scope 1 | 5,534,750 | 0,000,000 | 0,000,000 |
| Scope 2 | 14,133,210 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shanghai Henlius Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
